We report the case of a 55-year-old male European who became septic after he returned from a four-week holiday to Uganda. Soon after, he was diagnosed with severe falciparum malaria and developed multi-organ failure. Due to the worsening condition of the patient, drotrecogin alfa (activated) was started, soon after which the patient's condition significantly improved. He returned home on day 36 after admission, without neurologic sequelae.
CASE HISTORY
We report the case of a 55-year-old male European suffering from severe falciparum malaria who became septic and received recombinant drotrecogin alfa (activated). The patient had been on a fourweek holiday in Uganda and he had not taken any chemoprophylaxis against malaria. Three days after his return, he developed fever up to 40°C and diarrhoea with bloody stools. He was initially admitted to a peripheral hospital where a colonoscopy was performed and he was diagnosed with mild colitis. Blood count demonstrated thrombocytopenia of 30×10 9 /l. Blood film showed a mono-infection with Plasmodium falciparum. The patient was transferred to our tertiary care hospital. On admission, the patient's temperature was 40.1°C. He was awake and responsive but agitated and somewhat disoriented with a Glasgow Coma Scale varying between 8 and 10. The initial diagnosis was verified, with parasitaemia of 500,000 trophozoites per microlitre. Several blood cultures were drawn and the patient received a loading dose of quinine and clindamycin under constant monitoring of electrocardiogram, blood pressure and S a O 2 . Due to his deteriorating neurological state and the strong suspicion of cerebral malaria, he was then immediately transferred to our intensive care unit.
Three hours later, laboratory results showed decreasing platelet count, prolonged prothrombin time, low blood glucose and increasing lactate consistent with a disseminated intravascular coagulopathy (DIC) score of 8 1 , but the patient showed no signs of serious bleeding. The patient received platelet concentrates and fresh frozen plasma. Cranial computed tomography scan showed brain oedema. Evolving kidney failure with anuria despite adequate volume substitution and shock necessitating vasopressors were consistent with the diagnosis of multi-organ failure.
Within the next 48 hours, the patient still had a fever of 40°C. Trophozoite count remained high despite ongoing therapy. Lactate and lactate dehydrogenase remained elevated. Cranial computed tomography scan still showed signs of brain oedema and multiple, small, post-ischaemic lesions as signs of microangiopathy. Respiratory failure ensued and the patient was mechanically ventilated. Chest X-ray showed an acute respiratory distress syndrome pattern. Continuous veno-venous haemofiltration was initiated. Laboratory results still showed a low platelet count and signs of haemolysis. Due to the worsening condition of the patient despite maximal antimicrobial and supportive therapy, drotrecogin alfa (activated) was commenced at 24 µg.kg -1 for 96 hours.
Within hours of beginning treatment, the patient began to improve. Vasopressor dose was reduced gradually and stopped on day 13. Concomitantly, pulmonary gas exchange improved and the patient was weaned from the ventilator on day 14. Platelet count increased, while coagulation parameters and signs of haemolysis slowly normalised (Table 1) . Urine production also resumed on day 13 and continuous veno-venous haemofiltration was ceased on day 15. The patient required ongoing dialysis for two more weeks. A cranial computed tomograhy scan on day eight showed reduced oedema, so that analgesia and sedation could be ceased. On day 15 after intensive care unit admission, the patient was transferred to an open ward. He still had a slightly altered neurologic state, awake but agitated, and responded adequately. He was discharged on day 36 after admission without neurologic sequelae.
DISCUSSIOn
Malaria is a common cause of death worldwide, especially in tropical and sub-tropical areas, and therefore a huge public health problem 2 . As global travelling increases, there is a substantial increase in the number of imported cases of malaria 3 . Therefore, whenever a patient with fever of unknown origin returns from a foreign country where malaria is endemic, exclusion or definite diagnosis of malaria is mandatory. Severe malaria has to be treated as an emergency, as it can progress rapidly and lead to the death of the patient within hours 4, 5 . Mortality of severe malaria in industrial countries remains about 20%, despite advances in treatment and intensive therapy. Frequent complications of malaria include circulatory collapse, renal failure, DIC and sometimes cerebral manifestations, usually accompanied by a poor prognosis 6 .
In our department, 104 patients were admitted with malaria between 1992 and 1999, 66% of whom were diagnosed with P. falciparum 5 . Seven patients were admitted to the intensive care unit, four of them required mechanical ventilation and three died. Four patients suffered from cerebral involvement. All patients who died showed signs of brain oedema and DIC. Both conditions were associated with poor outcome.
Cerebral malaria is thought to be due to sequestration and clogging of parasitised red blood cells in the cerebral microcirculation, due to decreased deformability, endothelial adhesion, cytokine-mediated injury and inflammation and increased permeability of the blood-brain barrier leading to brain oedema 7 . Patients can show altered sensorium, seizures and sometimes coma. Moreover, excessive activation of the coagulation cascade leading to DIC and ensuing microthrombosis in pre-capillary vessels of the brain can aggravate the symptoms 8 . DIC leads to low levels of protein C in plasma of malaria patients which increase during adequate substitution 9 . Therefore, it seems reasonable that a drug like drotrecogin alfa may be useful in cases of severe malaria.
Recombinant human protein C (drotrecogin alfa [activated], Xigris ® ) is licenced for the treatment of severe sepsis. It was shown to inhibit coagulation factors Va and VIIIa and to partly antagonise the procoagulant state in severe sepsis 10, 11 . A randomised, controlled study showed a significant reduction in mortality of patients suffering from severe sepsis and septic shock 10, 12 . In every trial, drotrecogin alfa (activated) was administered as soon as possible. In our case, drotrecogin alfa (activated) was given late in the course of disease despite existing contraindications, in an attempt to stabilise the continuing deterioration with the risk of imminent death of the patient. Literature on the use of drotrecogin alfa in cases of severe malaria is rare. kendrick et al 13 reported a case of severe falciparum malaria in which drotrecogin alfa was included in the standard treatment. Soon after the initiation of the therapy, the patient's condition stopped deteriorating and began to improve. The patient returned home seven weeks after admission. In this specific case, an exchange transfusion was performed, although no clear evidence advocating this measure exists 14 . nevertheless, kendrick conceded that sepsis in this specific case could have also been induced due to concomitant bacterial infection. Due to the fact that multiple blood cultures drawn before and consecutively after administration of the first antibiotic loading dose were all negative, we presume that in our case severe sepsis was malaria-related.
Rankin et al 15 reported a case similar to ours. In this case, activated protein C also seemed to have a beneficial effect on the outcome. Again, soon after beginning the treatment with drotrecogin alfa, the patient's condition began to improve within hours. nevertheless, Rankin reported only a mild to moderate load of Plasmodium falciparum, and also could not exclude co-infection with Plasmodium vivax or other co-infections.
Srinivas et al 16 reported a case of a 25-year-old male with falciparum malaria and co-infection with Leptospira. The severity of endothelial clogging was considered responsible for the rather slow improvement of their patient, which we also observed in our patient.
Finally, nau et al 17 also discussed the use of drotrecogin alfa (activated), presenting a patient who suffered from severe malaria and who significantly improved after administration of drotrecogin alfa (activated). One has to also be aware that there is a bias towards publishing only positive results in case reports. It is therefore not known how many treatment attempts with drotrecogin alfa (activated) there have been so far and how many failed. As no prospective study on this topic has been yet performed, one has to carefully weigh between potential benefits and risks for the patient, as proposed by Bruneel 18 .
Because of the neurologic symptoms and the progressive multiple organ failure of our patient despite maximal supportive therapy, we decided to administer drotrecogin alfa. We believe that in this case, the administration of drotrecogin alfa substantially contributed to improving the patient's condition. Looking at the poor but growing evidence of the use of drotrecogin alfa in severe forms of malaria, it seems reasonable to at least consider its administration in patients with severe falciparum malaria with DIC and cerebral involvement who do not respond to or deteriorate during standard treatment.
Drotrecogin alfa may exert a positive effect on the outcome in severe malaria leading to multiorgan failure and seems to exert its beneficial effects within hours. Patients who survive their acute illness seem to recover without any or with only minor sequelae.
